Drug Profile
Research programme: anti-infectives - EPIRUS Biopharmaceuticals
Alternative Names: CRx-808Latest Information Update: 28 Jul 2016
Price :
$50
*
At a glance
- Originator CombinatoRx
- Developer EPIRUS Biopharmaceuticals; National Institute of Allergy and Infectious Diseases; United States Army Medical Research Institute of Infectious Diseases
- Class Small molecules
- Mechanism of Action Anthrax toxin inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alphavirus infections; Anthrax; Ebola virus infections; Hepatitis B; Hepatitis C
Most Recent Events
- 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
- 17 Jul 2014 No development reported - Preclinical for Alphavirus Infections in USA (unspecified route)
- 17 Jul 2014 No development reported - Preclinical for Anthrax in USA (unspecified route)